• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Roche, AstraZeneca launch early research data-sharing consortium

Roche, AstraZeneca launch early research data-sharing consortium

July 2, 2013
CenterWatch Staff

Roche and AstraZeneca are collaborating to share early research data related to drug design to further accelerate discovery of high-quality compounds with an increased chance of clinical success.

Using a dedicated technology called Matched Molecular Pair Analysis (MMPA), modifications will be identified that companies can apply to their compound structures to improve their metabolism, pharmacokinetics or safety without divulging confidential information about their chemical structures. This gives both companies the opportunity to reapply useful medicinal chemistry know-how embedded in their combined databases of experimental results, to identify potential new drug candidates using fewer rounds of design, synthesis and testing.

"AstraZeneca has taken multiple steps to both open our compound libraries to those wishing to find new chemistries for early drug discovery and to share compound-related datasets that will allow our industry to speed the discovery of new medicines," said Mike Snowden, head of Discovery Sciences in Innovative Medicines and Early Development (IMED), which initiated the collaboration.

The data-sharing will be managed through an intermediary company, MedChemica, which has expertise in MMPA. The consortium is open to other large companies to add their knowledge, to gain access to and enhance the resource.

Upcoming Events

  • 24May

    Powering an Effective Oversight Strategy with Clinical and Operational Insights

  • 25May

    2022 WCG Avoca Quality & Innovation Summit: Own the Future

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 16Oct

    WCG MAGI's Clinical Research Hybrid Conference - 2022 West

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Protocol-360x240.png

    Avoid Deviations by Making Protocol Review a Team Effort

  • SelectionProcess-360x240.png

    Give Us a Voice: Sites Clamor for a Say on Vendor Selection

  • Convince-360x240.png

    Use Data and Details to Convince Site Leadership to Add Staff

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing